Amantadine
Treatment for Parkinson S Disease
Typical Dosage: 100 mg twice daily
Effectiveness
55%
Safety Score
70%
Clinical Trials
32
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
100 mg twice daily
Time to Effect
1-2 weeks
Treatment Duration
Long-term (as needed for LID)
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$100
Side Effect Mgmt:$100
Total Annual:$400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$40,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$800
Prescription Access Economics
Annual Societal Loss per Patient
$660
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$500/year
Time Cost
$80/year
Travel + wait time
Insurance Admin Cost
$30/year
Prior auth, claims
Rx Price
$200/year
Potential OTC Price
$100/year
Estimated if OTC available
Early Treatment Benefit
+0.02 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
MODERATERequires Monitoring
YesNeeds lab work/checkups
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
12 completed trials for Amantadine in Parkinson S Disease
Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)
NCT00632762COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Aix-en-Provence, France +4 more
Started: Nov 1, 2007
Validation of Dyskinesia Rating Scales
NCT01071395COMPLETEDPHASE4
68 participants
INTERVENTIONAL
Birmingham, United States +7 more
Started: Jan 1, 2010
Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease
NCT01313845COMPLETEDPHASE4
46 participants
INTERVENTIONAL
Seongnam, South Korea +3 more
Started: Feb 1, 2011
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
NCT04387773COMPLETEDPHASE4
8 participants
INTERVENTIONAL
Portland, United States
Started: Nov 5, 2020
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
NCT01397422COMPLETEDPHASE2, PHASE3
83 participants
INTERVENTIONAL
Sun City, United States +32 more
Started: Jul 1, 2011
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
NCT00627640COMPLETEDPHASE3
549 participants
INTERVENTIONAL
Birmingham, United States +120 more
Started: Feb 1, 2009
A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease
NCT07113015COMPLETEDNA
220 participants
INTERVENTIONAL
Multan, Pakistan
Started: Jul 5, 2024
Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease
NCT01538329COMPLETEDPHASE2
210 participants
INTERVENTIONAL
Aix-en-Provence, France +17 more
Started: Mar 4, 2012
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
NCT02274766COMPLETEDPHASE3
77 participants
INTERVENTIONAL
Fountain Valley, United States +50 more
Started: Oct 1, 2014
Open-Label Safety Study of ADS-5102 in PD Patients With LID
NCT02202551COMPLETEDPHASE3
223 participants
INTERVENTIONAL
Birmingham, United States +86 more
Started: Jul 1, 2014
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
NCT02136914COMPLETEDPHASE3
126 participants
INTERVENTIONAL
Birmingham, United States +45 more
Started: May 1, 2014
Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease
NCT04730245COMPLETEDPHASE1
14 participants
INTERVENTIONAL
León, Mexico
Started: Jun 1, 2018
Showing 20 of 32 total trials